Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712280 · ClinicalTrials.gov registry record · Phase 2
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
A Phase 2 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03712280 is a Phase 2 study that has completed, run by Mallinckrodt. The registered enrollment target is 50 participants.
The verdict
NCT03712280, a Phase 2 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
Interventions
- DRUG Rifaximin
- DRUG MNK6106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2020-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712280
The ClinicalTrials.gov registry entry for NCT03712280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifaximin is the first listed.
NCT03712280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712280 about?
NCT03712280 is a clinical study titled "MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)". The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
What is the current status of trial NCT03712280?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-12-01. Estimated completion is 2020-07-14.
What interventions are being tested in trial NCT03712280?
The interventions under investigation include: Rifaximin (DRUG), MNK6106 (DRUG).
Who is sponsoring clinical trial NCT03712280?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.